Back to search

National and Kapodistrian University of Athens

Μηχανισμός ανάπτυξης και θεραπευτική αντιμετώπιση της χοριοειδικής νεοαγγείωσης της ωχράς κηλίδας σε ασθενείς με παθολογικό υπόστρωμα: αγγειοειδείς ταινίες

Abstract

dc:description

Introduction: Macular choroidal neovascularization (CNV) is the most serious complication of Angioid streaks (AS). It has a poor natural course usually resulting in central visual loss. Treatment of CNV in patients with AS with laser photocoagulation, photodynamic therapy and submacular surgery were not effective. Intravitreal injections of vascular endothelial growth factor (anti-VEGF) drugs is currently the most effective treatment. However, published case series report on the final effect of anti-VEGF therapy on the best corrected visual acuity (BCVA). No one study has compared the functional outcomes, i.e., BCVA, by the end of the first and second year of therapy. Purpose: The aim of our study was to compare 12 and 24-month results of intravitreal ranibizumab therapy in the management of choroidal neovascularization (CNV) secondary to angioid steaks (ST). This could be of clinical importance helping us planning optimal dosing strategies. Design: 24-month prospective, open-label, interventional clinical study. Methods: Over a 7-year period, a consecutive series of treatment-naive eyes with macular CNV due to AS were treated with intravitreal ranibizumab (0.5 mg). The main outcome measure was changes in best-corrected visual acuity (BCVA) at 12 and 24 months as compared to baseline. Results: Twenty eyes completed 24-month therapy and regular follow up. Each eye received a median of 7 (7-10) and 2 (1-5) injections during the first and the second year, respectively. BCVA was improved at 12 (0.42±0.26 logMAR) and 24 months (0.44±0.22 logMAR) as compared to baseline (0.75±0.26 logMAR) (p<0.001), but did not change between the 12 and 24-month follow up (p=0.48). BCVA was improved in 15 (75%) and 16 (80%) of the eyes, but in 4 (20%) and 3 (15%) remain unchanged (p=0.92) at 12 and 24 months, respectively. Central retinal thickness was reduced at 12 (287±87 μm) and 24 months (322±98 μm) as compared to baseline (382±96 μm) (p<0.001), but did not change between the 12 and 24-month (p=0.14). No injection or drug-related side-effects were observed. Conclusion: Our 24-month prospective study have clearly shown that intravitreal injections of ranibizumab in patients with macular CNV secondary to AS improves visual acuity during the first year and stabilizes it during the second year of therapy. We can postulate that it is mostly the treatment during the first year that leads to functional and anatomical improvement while, during the second year, treatment mainly preserves the first-year results.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2015

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ladas, Dimitrios
  • Λαδάς, Δημήτριος

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/42426

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ladas, Dimitrios; Λαδάς, Δημήτριος. Μηχανισμός ανάπτυξης και θεραπευτική αντιμετώπιση της χοριοειδικής νεοαγγείωσης της ωχράς κηλίδας σε ασθενείς με παθολογικό υπόστρωμα: αγγειοειδείς ταινίες. National and Kapodistrian University of Athens, 2015. http://hdl.handle.net/10442/hedi/42426